Arundathy N.  Pandite net worth and biography

Arundathy Pandite Biography and Net Worth

Insider of Shattuck Labs

Lini joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings more than 25 years of academic, medical, and pharmaceutical experience. Her broad oncology drug development expertise spans early-to-late phase development from Pre-IND through registration and commercialization. Prior to joining Shattuck, Lini was Head of Global Clinical Development and Senior Vice President at Adaptimmune, responsible for clinical development of the company’s immuno-oncology pipeline. She spent several years with GlaxoSmithKline (GSK) culminating her tenure as, Vice President R&D and Head Unit Physician for Oncology. While at GSK, Lini was instrumental in leading the development of several compounds. Lini practiced medicine in both the United Kingdom and the United States and is Board Certified in Hematology and Oncology. Lini was an attending physician at Dana Farber Cancer Institute in Boston and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at Harvard University and the University of Miami. She received her medical degree from The University of Liverpool, England and a Master’s in Business Administration from the Fuqua School of Business at Duke University.

What is Arundathy N. Pandite's net worth?

The estimated net worth of Arundathy N. Pandite is at least $872.76 thousand as of June 30th, 2026. Pandite owns 136,219 shares of Shattuck Labs stock worth more than $872,755 as of July 14th. This net worth evaluation does not reflect any other assets that Pandite may own. Learn More about Arundathy N. Pandite's net worth.

How do I contact Arundathy N. Pandite?

The corporate mailing address for Pandite and other Shattuck Labs executives is , , . Shattuck Labs can also be reached via phone at 512-900-4690 and via email at [email protected]. Learn More on Arundathy N. Pandite's contact information.

Has Arundathy N. Pandite been buying or selling shares of Shattuck Labs?

Arundathy N. Pandite has not been actively trading shares of Shattuck Labs during the last ninety days. Most recently, Arundathy N. Pandite sold 30,000 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a transaction totalling $210,300.00. Following the completion of the sale, the insider now directly owns 136,219 shares of the company's stock, valued at $954,895.19. Learn More on Arundathy N. Pandite's trading history.

Who are Shattuck Labs' active insiders?

Shattuck Labs' insider roster includes Mona Ashiya (Director), Tyler Brous (Director), Josiah Hornblower (Director), Andrew Neill (CFO), Arundathy Pandite (Insider), Taylor Schreiber (CEO), Abhinav Shukla (Chief Technical Officer), Clay Siegall (Director), and Erin Thomson (General Counsel). Learn More on Shattuck Labs' active insiders.

Are insiders buying or selling shares of Shattuck Labs?

In the last twelve months, Shattuck Labs insiders bought shares 3 times. They purchased a total of 12,674,754 shares worth more than $11,222,660.98. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 85,907 shares worth more than $591,849.62. The most recent insider tranaction occured on July, 2nd when insider Abhinav A Shukla sold 410 shares worth more than $2,874.10. Insiders at Shattuck Labs own 8.8% of the company. Learn More about insider trades at Shattuck Labs.

Information on this page was last updated on 7/2/2026.

Arundathy N. Pandite Insider Trading History at Shattuck Labs

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2026Sell30,000$7.01$210,300.00136,219View SEC Filing Icon  
5/12/2026Sell30,000$6.61$198,300.00166,219View SEC Filing Icon  
See Full Table

Arundathy N. Pandite Buying and Selling Activity at Shattuck Labs

This chart shows Arundathy N Pandite's buying and selling at Shattuck Labs by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shattuck Labs Company Overview

Shattuck Labs logo
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $6.29
Low: $6.20
High: $6.53

50 Day Range

MA: $5.89
Low: $3.90
High: $7.26

2 Week Range

Now: $6.29
Low: $0.71
High: $8.33

Volume

749,923 shs

Average Volume

846,890 shs

Market Capitalization

$482.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05